Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes

被引:65
作者
Wu, Yanheng [1 ]
Gu, Wenyi [1 ]
Li, Jiang [2 ]
Chen, Chen [3 ]
Xu, Zhi Ping [1 ]
机构
[1] Univ Queensland, Australian Inst Bioengn & Nanotechnol, St Lucia, Qld 4072, Australia
[2] Sun Yat Sen Univ, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
[3] Univ Queensland, Queensland Brain Inst, Sch Biomed Sci, St Lucia, Qld 4072, Australia
关键词
breast cancer; cytokines; MCF-7; nanoparticles delivery; PD-1; PD-L1; siRNA; TILs; CALCIUM-PHOSPHATE NANOPARTICLES; CELL TRANSFER; CANCER; EXPRESSION; BREAST; SIRNA; IMMUNOTHERAPY; INHIBITION; BLOCKADE; GROWTH;
D O I
10.2217/nnm-2018-0237
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Aim: To determine if silencing PD-1 on tumor-infiltrating lymphocytes (TILs) and its ligand-1 (PD-L1) on cancer cells will enhance the cytotoxicity of TILs. Materials & methods: Lipid-coated calcium phosphate nanoparticles were synthesized to deliver siRNAs against PD-1 and PD-L1 to TILs and breast cancer MCF-7 cells. The downregulation of PD-1/PD-L1 expressions was determined by real-time PCR and western blotting assays. The killing efficacy of TILs to MCF-7 cells was determined by cytotoxic T lymphocyte assay. Results: Lipid-coated calcium phosphate nanoparticles effectively delivered siRNAs and silenced PD-1 and PD-L1sh expression. The knockdown of either gene or both greatly improved the cytotoxicity of TILs. Conclusion: Silencing PD-1 and PD-L1 is an effective approach to increase TIL cytotoxicity to cancer cells.
引用
收藏
页码:955 / 968
页数:14
相关论文
共 44 条
[1]   PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction [J].
Abiko, Kaoru ;
Mandai, Masaki ;
Hamanishi, Junzo ;
Yoshioka, Yumiko ;
Matsumura, Noriomi ;
Baba, Tsukasa ;
Yamaguchi, Ken ;
Murakami, Ryusuke ;
Yamamoto, Ayaka ;
Kharma, Budiman ;
Kosaka, Kenzo ;
Konishi, Ikuo .
CLINICAL CANCER RESEARCH, 2013, 19 (06) :1363-1374
[2]   Inhibition of respiratory viruses by nasally administered siRNA [J].
Bitko, V ;
Musiyenko, A ;
Shulyayeva, O ;
Barik, S .
NATURE MEDICINE, 2005, 11 (01) :50-55
[3]   Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].
Brahmer, Julie R. ;
Drake, Charles G. ;
Wollner, Ira ;
Powderly, John D. ;
Picus, Joel ;
Sharfman, William H. ;
Stankevich, Elizabeth ;
Pons, Alice ;
Salay, Theresa M. ;
McMiller, Tracee L. ;
Gilson, Marta M. ;
Wang, Changyu ;
Selby, Mark ;
Taube, Janis M. ;
Anders, Robert ;
Chen, Lieping ;
Korman, Alan J. ;
Pardoll, Drew M. ;
Lowy, Israel ;
Topalian, Suzanne L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175
[4]   Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy [J].
Chen, Yunching ;
Zhu, Xiaodong ;
Zhang, Xiaoju ;
Liu, Bin ;
Huang, Leaf .
MOLECULAR THERAPY, 2010, 18 (09) :1650-1656
[5]   IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2 [J].
Cochaud, Stephanie ;
Giustiniani, Jerome ;
Thomas, Clemence ;
Laprevotte, Emilie ;
Garbar, Christian ;
Savoye, Aude-Marie ;
Cure, Herve ;
Mascaux, Corinne ;
Alberici, Gilles ;
Bonnefoy, Nathalie ;
Eliaou, Jean-Francois ;
Bensussan, Armand ;
Bastid, Jeremy .
SCIENTIFIC REPORTS, 2013, 3
[6]   Chimeric Antigen Receptor T Cells for Cancer Immunotherapy [J].
Curran, Kevin J. ;
Brentjens, Renier J. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) :1703-+
[7]   Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production [J].
Curran, Michael A. ;
Kim, Myoungjoo ;
Montalvo, Welby ;
Al-Shamkhani, Aymen ;
Allison, James P. .
PLOS ONE, 2011, 6 (04)
[8]  
Gros A, 2014, J CLIN INVEST, V124, P2246, DOI [10.1172/JC173639, 10.1172/JCI73639]
[9]   Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes [J].
Gu, W. ;
Putral, L. ;
Hengst, K. ;
Minto, K. ;
Saunders, N. A. ;
Leggatt, G. ;
McMillan, N. A. J. .
CANCER GENE THERAPY, 2006, 13 (11) :1023-1032
[10]   Both treated and untreated tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses [J].
Gu, Wenyi ;
Cochrane, Melanie ;
Leggatt, Graham R. ;
Payne, Elizabeth ;
Choyce, Allison ;
Zhou, Fang ;
Tindle, Robert ;
McMillan, Nigel A. J. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (20) :8314-8319